Home / Health / Pfizer Advances Monthly GLP-1 RA for Weight Management
Pfizer Advances Monthly GLP-1 RA for Weight Management
8 Jun
Summary
- Berobenatide shows competitive weight loss in obesity and type 2 diabetes.
- Monthly GLP-1 RA demonstrates favorable tolerability with low adverse events.
- Pfizer's Phase III trials for obesity are extensive, aiming for 2026 completion.
Pfizer has reported significant Phase IIb findings for its potential first-in-class monthly glucagon-like peptide-1 receptor agonist (GLP-1 RA) peptide, berobenatide, aimed at treating obesity and type 2 diabetes.
Clinical trials, including VESPER-1, VESPER-2, and VESPER-3, examined both weekly and monthly dosing regimens. These studies demonstrated berobenatide's capacity for substantial weight loss and a favorable tolerability profile, marked by a low incidence of gastrointestinal side effects and minimal discontinuation rates even with rapid dose escalations.
An exploratory extension of the VESPER-1 study showed a 15.9% non-placebo-adjusted weight loss at 60 weeks for participants on a 2.4mg weekly dose. In individuals with type 2 diabetes, VESPER-2 indicated a 2.2% reduction in HbA1c with berobenatide use over 28 weeks.
Pfizer is now actively enrolling patients in pivotal Phase III trials, including VESPER-6 for monthly maintenance dosing and SOLIS-1, which is evaluating an ultra-long-acting amylin analogue, PF-3945, alone and in combination with berobenatide. The company anticipates conducting over 20 trials by 2026 for obesity and related conditions.
